Form 8-K · Current Report · Filed 2024-05-07
Ionis Pharmaceuticals Announces Q1 2024 Financial Results and Pipeline Updates
Ionis Pharmaceuticals, Inc. reported its financial results for the first quarter of 2024, showing a total revenue of $119 million, a slight decrease from $131 million in Q1 2023. The company's commercial revenue included royalties from the launch of WAINUA in the U.S. and SPINRAZA globally. Ionis also provided updates on its pipeline, including the submission of an NDA for olezarsen to the FDA and positive Phase 3 data for donidalorsen in patients with HAE. The company's cash and short-term investments stood at $2.2 billion as of March 31, 2024.
- Filer
- Ionis Pharmaceuticals Inc. IONS · NASDAQ
- Filed
- Accession
- 0001140361-24-024648
- CIK
- 0000874015
- Signal
- Low impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Results of Operations and Financial Condition
Financial Statements and Exhibits
Market reaction
Close before filing
$42.28
Next session
-5.0%
Since filing
+22.4%
Latest close
$51.77
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from IONS reporting the same item, with the next session's move:
Exhibits (1)
About Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals Inc. is a biotechnology company focused on discovering and developing RNA-targeted therapeutics. The primary mission of Ionis is to harness its expertise in antisense oligonucleotide technology to address complex genetic disorders. Ionis is pioneering in the field of RNA-targeted drug discovery, aiming to treat a wide range of diseases, including neurological, cardiovascular, metabolic, and cancer-related conditions. Notably, the company has a robust pipeline of drugs in various stages of development and partnerships with leading pharmaceutical companies to expand the reach and impact of its therapeutic discoveries. As an innovative entity in the biotechnology sector, Ionis Pharmaceuticals plays a significant role in advancing medical treatments that target the underlying genetic causes of diseases, thereby offering new hope and potential solutions to patients worldwide. Its advancements contribute substantially to the growth and evolution of personalized medicine, emphasizing the importance of genetic research in modern healthcare.
Never miss another IONS filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.